Blinatumomab is a BiTE (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL); however, a subset of patients relapse. Monitoring expression of cluster of differentiation (CD)19 in relapsed patients is critical to inform sequencing of subsequent therapies. The expression of CD19 in 59 pediatric patients with R/R B-ALL was analyzed on the day of diagnosis of R/R B-ALL and on days 15 and 29 of cycle 1 of blinatumomab. Most patients treated with one cycle of blinatumomab retained expression of CD19, and would therefore be eligible for subsequent anti-CD19 CAR T-cell therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.29323DOI Listing

Publication Analysis

Top Keywords

r/r b-all
12
pediatric patients
8
b-cell precursor
8
precursor acute
8
acute lymphoblastic
8
lymphoblastic leukemia
8
expression cd19
8
cycle blinatumomab
8
patients
6
cd19
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!